PL2238458T3 - Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości - Google Patents

Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości

Info

Publication number
PL2238458T3
PL2238458T3 PL08867898T PL08867898T PL2238458T3 PL 2238458 T3 PL2238458 T3 PL 2238458T3 PL 08867898 T PL08867898 T PL 08867898T PL 08867898 T PL08867898 T PL 08867898T PL 2238458 T3 PL2238458 T3 PL 2238458T3
Authority
PL
Poland
Prior art keywords
obesity
pharmaceutical agent
predicting responsiveness
pharmaceutical therapy
biomarker
Prior art date
Application number
PL08867898T
Other languages
English (en)
Inventor
Jennifer K Leohr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2238458(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2238458T3 publication Critical patent/PL2238458T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08867898T 2007-12-19 2008-12-18 Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości PL2238458T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1488107P 2007-12-19 2007-12-19
EP08867898A EP2238458B1 (en) 2007-12-19 2008-12-18 Method for predicting responsiveness to a pharmaceutical therapy for obesity
PCT/US2008/087367 WO2009085917A1 (en) 2007-12-19 2008-12-18 Method for predicting responsiveness to a pharmaceutical therapy for obesity

Publications (1)

Publication Number Publication Date
PL2238458T3 true PL2238458T3 (pl) 2012-03-30

Family

ID=40386209

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08867898T PL2238458T3 (pl) 2007-12-19 2008-12-18 Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości

Country Status (17)

Country Link
US (2) US8355877B2 (pl)
EP (2) EP2238458B1 (pl)
JP (1) JP5242701B2 (pl)
KR (2) KR101240875B1 (pl)
AT (1) ATE530916T1 (pl)
AU (2) AU2008343177B2 (pl)
BR (2) BRPI0821364A2 (pl)
CA (2) CA2710248A1 (pl)
CY (1) CY1112352T1 (pl)
DK (1) DK2238458T3 (pl)
ES (1) ES2373625T3 (pl)
HR (1) HRP20110840T1 (pl)
MX (1) MX2010006890A (pl)
PL (1) PL2238458T3 (pl)
PT (1) PT2238458E (pl)
SI (1) SI2238458T1 (pl)
WO (2) WO2009085927A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104749333A (zh) * 2009-07-22 2015-07-01 伊莱利利公司 预测与药物治疗相关的重量增加的方法
WO2014204990A2 (en) * 2013-06-18 2014-12-24 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Methods of predicting of chemical properties from spectroscopic data
WO2016065463A1 (en) * 2014-10-28 2016-05-06 2352409 Ontario Inc. Methods for providing personalized diet and activity recommendations that adapt to the metabolism of each dieter individually using frequent measurements of activity and triglyceride levels
KR102397234B1 (ko) 2020-09-17 2022-05-12 가천대학교 산학협력산 약물 순응도 평가 방법 및 시스템

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO2000051054A1 (en) 1999-02-26 2000-08-31 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
WO2003012416A1 (en) * 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
CA2477614A1 (en) * 2002-03-05 2003-09-18 Merck & Co., Inc. Biomarker for efficacy of appetite suppressant drugs
CA2561536C (en) * 2004-04-01 2017-09-19 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.

Also Published As

Publication number Publication date
EP2238458A1 (en) 2010-10-13
DK2238458T3 (da) 2012-01-23
ATE530916T1 (de) 2011-11-15
BRPI0821364A2 (pt) 2015-06-16
WO2009085927A1 (en) 2009-07-09
US8084261B2 (en) 2011-12-27
EP2235544A1 (en) 2010-10-06
PT2238458E (pt) 2012-01-11
MX2010006890A (es) 2010-09-30
BRPI0821051B1 (pt) 2022-02-08
HRP20110840T1 (hr) 2011-12-31
CY1112352T1 (el) 2015-12-09
WO2009085917A1 (en) 2009-07-09
CA2710395C (en) 2016-10-18
CA2710248A1 (en) 2009-07-09
KR20100088624A (ko) 2010-08-09
CA2710395A1 (en) 2009-07-09
JP5242701B2 (ja) 2013-07-24
AU2008343177B2 (en) 2013-09-26
EP2238458B1 (en) 2011-10-26
US20100248375A1 (en) 2010-09-30
KR20100084577A (ko) 2010-07-26
ES2373625T3 (es) 2012-02-07
JP2011508218A (ja) 2011-03-10
US20100268474A1 (en) 2010-10-21
AU2008343177A1 (en) 2009-07-09
US8355877B2 (en) 2013-01-15
KR101240875B1 (ko) 2013-03-08
AU2008343187A1 (en) 2009-07-09
SI2238458T1 (sl) 2012-02-29
BRPI0821051A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
EP2203112A4 (en) METHOD, SYSTEM AND COMPUTER SIMULATION ENVIRONMENT FOR VERIFICATION OF MONITORING AND CONTROL STRATEGIES AT DIABETES
EP2587473A4 (en) ACTIVE MATRIX SUBSTRATE, DISPLAY DEVICE AND METHOD FOR TESTING THE ACTIVE MATRIX SUBSTRATE OR DISPLAY DEVICE
WO2012078806A3 (en) Non-gaming on-line achievement awards
EP2219130A4 (en) METHOD AND APPARATUS FOR DETECTING THE MALICIOUS BEHAVIOR OF A COMPUTER PROGRAM
EP2589937A4 (en) VERIFICATION SYSTEM FOR A LARGE WEIGHING MACHINE AND LOADING AND DISCHARGE MEASURING DEVICE WITH AUTOMATIC LOCALIZATION
EP2330506A4 (en) METHOD AND DEVICE FOR INTERRUPT LOAD COMPENSATION FOR MULTICORE PROCESSORS
WO2008135986A3 (en) System, method and device for comprehensive individualized genetic information or genetic counseling
MY164394A (en) Device and method for determining information related to a medical device
NZ602497A (en) Enterobacter sp. 638 and methods of use thereof
AR071165A1 (es) Metodos y aparatos para la recuperacion de inversion en dispositivos medicos
PH12015500545A1 (en) Methods for modulating corticosterone levels in psychologically stressed individuals
WO2012067970A3 (en) Transcriptional repression leading to parkinson's disease
BRPI0916174A2 (pt) "sistema de exibição, método e produto de programa de computador"
EP2354948A4 (en) DEVICE FOR SUPPORTING THE DETECTION OF A DEFECT EVENT, METHOD FOR SUPPORTING THE DETECTION OF A DEFECT EVENT, AND COMPUTER PROGRAM
IL208723A0 (en) Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
HK1142675A1 (en) Method for improving the ability to detect materials in an x-ray test system, and x-ray test system
BRPI0917616A2 (pt) arranjo para medir a velocidade local de um líquido que contém um material magnético em uma veia dentro de uma região de ação, método para medir a velocidade local de um líquido que contém um material magnético em uma veia dentro de uma região de ação e programa de computador
EP2370931A4 (en) METHOD, APPARATUS AND COMPUTER PROGRAM FOR PROVIDING AN INDEPENDENT ORIENTATION FACIAL DETECTOR
GB2509647A (en) Testing transaction applications
EP2513336A4 (en) METHOD FOR CHARACTERIZING THE IMMUNE FUNCTION OF EX VIVO INDUCTIVE HOST OF OFFENSIVE AND DEFENSIVE IMMUNE MARKERS
PL2238458T3 (pl) Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości
MX337767B (es) Tecnologia de simulacion integrada.
IN2013CN00326A (pl)
GB201108692D0 (en) A method, apparatus and computer program product for determining the strain induced at a selected point in a stiffened panel structure in response to a load
FR2931613B1 (fr) Dispositif et procede de verification d'integrite d'objets physiques